Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant cause » significant change (Expand Search), significant changes (Expand Search), significant increase (Expand Search)
Showing 1,561 - 1,580 results of 21,342 for search '(( significant decrease decrease ) OR ( ((significant cause) OR (significant gap)) decrease ))', query time: 0.50s Refine Results
  1. 1561
    Potato gene ontology enrichment results significant at <i>p</i> < 0.01.

    Potato gene ontology enrichment results significant at <i>p</i> < 0.01. by Margaret A. Carpenter (6104180)

    Published 2025
    Save to List
    Saved in:
  2. 1562
    Genome-wide significant SNPs for meat L*15 min and a*15 min.

    Genome-wide significant SNPs for meat L*15 min and a*15 min. by Jiahong Sun (6497603)

    Published 2024
    Save to List
    Saved in:
  3. 1563
    Statistically Significant Results for Heart Rate Variability (HRV) Indices for High and Low Authority Groups.

    Statistically Significant Results for Heart Rate Variability (HRV) Indices for High and Low Authority Groups. by David Vagni (8060432)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 1564
    Statistically Significant Results for Heart Rate Variability (HRV) Indices for High and Low Clarity Groups.

    Statistically Significant Results for Heart Rate Variability (HRV) Indices for High and Low Clarity Groups. by David Vagni (8060432)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 1565
    Identification of ACADM, ANGPTL4, and NFKB2 as significant predictors of OS in the TCGA-KIRC cohort.

    Identification of ACADM, ANGPTL4, and NFKB2 as significant predictors of OS in the TCGA-KIRC cohort. by Yu Zhang (12946)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 1566
    EF-24 induces significant transcriptional changes in K-562 cells.

    EF-24 induces significant transcriptional changes in K-562 cells. by Ajeet P. Singh (22298432)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 1567
    Main baseline characteristics of patients included in the study.

    Main baseline characteristics of patients included in the study. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 1568
    (A) Monthly drug costs of patients in the ESAs group and Roxadustat group.

    (A) Monthly drug costs of patients in the ESAs group and Roxadustat group. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 1569
    Study data.

    Study data. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 1570
    Mean hemoglobin levels of Roxadustat and ESAs groups over time.

    Mean hemoglobin levels of Roxadustat and ESAs groups over time. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 1571
    Morisky score for ESAs group and Roxadustat group.

    Morisky score for ESAs group and Roxadustat group. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 1572
    Patient flow diagram.

    Patient flow diagram. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 1573
    Mean total cholesterol levels over time in the roxadustat group (A) and ESAs group (B) according to the statins subgroup.

    Mean total cholesterol levels over time in the roxadustat group (A) and ESAs group (B) according to the statins subgroup. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 1574
    Summary of clinical outcomes after 9 months.

    Summary of clinical outcomes after 9 months. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 1575
    Approval by the research ethics committee.

    Approval by the research ethics committee. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 1576
    (A) Changes of left ventricular ejection fraction over time in Roxadustat and ESAs groups.

    (A) Changes of left ventricular ejection fraction over time in Roxadustat and ESAs groups. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 1577
    Segmented regression analysis of time to intravenous antimicrobial administration (IVA) at intervention and control sites during the implementation period.

    Segmented regression analysis of time to intravenous antimicrobial administration (IVA) at intervention and control sites during the implementation period. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 1578
    Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Uganda during baseline and implementation periods.

    Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Uganda during baseline and implementation periods. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 1579
    Kenya: Enrolment, time to IVA, mortality, admissions and readmissions at sites in Kenya.

    Kenya: Enrolment, time to IVA, mortality, admissions and readmissions at sites in Kenya. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 1580
    Uganda: enrolment, time to IVA, mortality, admissions and readmissions.

    Uganda: enrolment, time to IVA, mortality, admissions and readmissions. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: